2024-10-15 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis Report

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and sells a wide range of medical devices, pharmaceuticals, and nutrition products.

**Performance Analysis:**

**1. Return Rate vs. S&P 500 (VOO):**

* **Cumulative Return:** ABT: 107.9%, VOO: 135.82%
* **Relative Return:** -27.92% (Relative to VOO) 
* **Relative Divergence:** 14.34% (This means the current divergence between ABT and VOO is at the 14.34th percentile of historical divergence between the two, with the maximum being 65.94% and minimum being -46.17%)

**2. Recent Price Fluctuation:**

* **Closing Price:** $116.12
* **5-Day Moving Average:** $115.18
* **20-Day Moving Average:** $114.29
* **60-Day Moving Average:** $111.81 

**3. Technical Indicators:**

* **RSI:** 56.77 (Neutral, indicating neither overbought nor oversold)
* **PPO:** 0.13 (Positive, indicating a potential for an upward trend)
* **Delta_Previous_Relative_Divergence:** -5.86 (Negative, indicating a short-term downward trend)
* **Expected Return:** 0.0% (Expected 5-year return relative to S&P 500)

**4. Recent Earnings and Outlook:**

| Date       | EPS    | Revenue   |
|-------------|--------|-----------|
| 2024-07-31 | 0.74   | 10.38 B$  | 
| 2024-05-02 | 0.7    | 9.96 B$  |
| 2023-11-01 | 0.82   | 10.14 B$ |
| 2023-08-03 | 0.79   | 9.98 B$  |
| 2023-07-31 | 0.79   | 9.98 B$  |

* The most recent earnings report for the quarter ending July 31, 2024, showed an EPS of $0.74 and revenue of $10.38 billion. While this represents a slight decrease from the previous quarter, it is important to note that analysts' expectations were not readily available. 

**5. News and Recent Issues:**

* **Recent Market Outlook:** ABT has shown a positive outlook in recent months, with investors remaining optimistic about the company's long-term prospects.
* **Analyst Opinions:** Many analysts are bullish on ABT's future, citing the company's diversified portfolio, strong brand recognition, and commitment to innovation. 
* **Performance Highlights:** ABT's consistent revenue growth, coupled with its ability to navigate market challenges effectively, has contributed to its positive market performance. 
* **FINBOLD**: According to FINBOLD, ABT has a strong financial profile with a high dividend yield and consistent growth prospects. However, the report also highlights potential risks associated with regulatory pressures and competitive landscapes in the healthcare industry.

**6. Comprehensive Analysis:**

ABT has consistently outperformed the market over the long term, with a strong dividend yield. Despite recent underperformance compared to the S&P 500,  the company remains financially healthy and well-positioned for long-term growth. 

**Technical indicators suggest a possible short-term downward trend, while longer-term outlook remains optimistic based on its fundamental strength. However, investors should remain cautious about potential regulatory risks and competition in the healthcare industry.**

**7. Conclusion:**

ABT represents a solid investment opportunity for investors seeking exposure to the healthcare sector. Its strong fundamentals and long-term growth potential make it an attractive option for both long-term and dividend-focused investors. However, investors should be aware of the potential risks associated with the healthcare industry and keep an eye on the company's performance and future prospects.
